Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.
We'd appreciate your feedback.Tell us what you think!
PharmaPendium is a DMPK solution combining comprehensive DMPK data from FDA and EMA documents with an innovative DDI predictor. With PharmaPendium, DMPK and regulatory scientists can quickly: • Characterize ADME properties • Predict drug-drug interactions (DDIs) • Connect preclinical results to clinical outcomes
"Because patient safety has always been a priority for Servier, we want to make sure that our drugs are optimally co-administered. Predicting pharmacokinetic Drug-Drug Interactions (DDI) with the maximum of relevance, precision and reactivity is therefore essential. DDIRC is therefore an essential tool … and enables rapid responses, hence decisions, on the interaction risks."
YP
Yannick Parmentier
Head of the Biopharmaceutical Research Department at Servier
PharmaPendium has the most comprehensive coverage of DMPK data from FDA and EMA documents on marketed and withdrawn drugs with full-text search.
The pharmacokinetic (PK) and metabolizing enzymes and transporters (MET) datasets in PharmaPendium leverage global regulatory intelligence to support drug candidate selection.
Make drug development decisions with confidence using the DMPK data in PharmaPendium.
The Drug-Drug Interaction Risk Calculator (DDIRC) is a DDI predictor that uses a mechanistic static modeling approach to quickly and transparently assess DDI risk. The DDIRC:
Was developed with Merck, Eli Lilly, Sanofi, Servier, Boehringer Ingelheim, Servier and Pierre Fabre to meet industry needs for improving patient safety
Meets FDA-recommended practices and is scientifically sound, regulator-ready and easy to apply
Captures key parameters (e.g., AUC) to guide dose adjustment, optimize therapeutic windows and ensure drug safety
PharmaPendium provides analytical tools to uncover critical DMPK insights from millions of lines of DMPK content within regulatory documents.
Analyze, compare and apply PK insights for safer and more effective drug development.
Filter MET experimental data to identify potential drug-drug interactions that could impact efficacy or cause serious adverse events.
Extract comparative data that supports dose selection, therapeutic window definition, risk assessments and modeling strategies.
Sanofi/DNDi use PharmaPendium's Drug-Drug Interaction Risk Calculator in successful EMA and FDA submissions
Learn how DDIRC predictions supported the authorization of fexinidazole.
